# GLP-1s a Viable Option to Treat, Prevent SUDs? – Medscape > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-receptor-agonists-substance-use-disorders/ > **Published:** 2026-03-16T08:30:36-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:59-04:00 > **Clinical Summary:** Explore how GLP-1 receptor agonists substance use disorders may offer new treatment options for addiction and metabolic conditions. --- ✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafety Why This Matters GLP-1 receptor agonists may offer clinicians a new pharmacological tool to address substance use disorders, including [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), which could expand treatment options beyond traditional addiction medications. This finding is particularly relevant for patients with concurrent metabolic conditions like obesity or diabetes who struggle with cannabis or other substance use, as a single medication could address multiple conditions simultaneously. Clinicians should stay informed about emerging evidence on GLP-1s for substance use prevention and treatment, as this could shift prescribing practices and improve outcomes for vulnerable patient populations. Clinical Summary A retrospective cohort study examining electronic health records found that patients prescribed GLP-1 receptor agonists demonstrated significantly lower incidence of substance use disorders, including cannabis use disorder, compared to matched controls without GLP-1 exposure. The protective association persisted across multiple substance classes including alcohol, cocaine, nicotine, and opioids, suggesting a potential class effect rather than a substance-specific mechanism. While the underlying biological mechanism remains unclear, GLP-1 agonists may modulate reward pathways or reduce impulsivity through effects on dopamine signaling and appetite regulation. These observational findings warrant prospective [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to determine whether GLP-1 agonists could serve as adjunctive therapy for patients at risk for or struggling with cannabis and other substance use disorders. Clinicians managing patients with concurrent metabolic disease and substance use concerns may cautiously consider GLP-1 agonists as part of a comprehensive treatment strategy, though current evidence remains preliminary and should not replace evidence-based [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). Dr. Caplan’s Take “What we’re seeing with GLP-1s is a pharmacological effect on reward circuitry that extends well beyond glucose metabolism, and cannabis use disorder appears responsive to this mechanism just as alcohol and opioid disorders are, which means we now have a legitimate tool to offer patients who struggle with cannabis dependence alongside their metabolic concerns.” Clinical Perspective Emerging evidence suggests GLP-1 receptor agonists may reduce substance use disorder risk across multiple drug classes, including cannabis, though clinicians should interpret these findings cautiously given that most data derive from observational studies with inherent confounding—patients prescribed GLP-1s may differ systematically from controls in health literacy, socioeconomic status, metabolic health, and motivation for treatment. The mechanistic basis for potential protective effects remains unclear and likely involves complex interactions between weight loss, improved glycemic control, altered reward pathway signaling, and general health engagement rather than a direct pharmacological action against substance craving. While these associations are intriguing for patients with comorbid metabolic and substance use disorders, current evidence does not support prescribing GLP-1s specifically for cannabis or other SUD prevention or treatment outside of well-designed clinical trials. Clinicians caring for patients with cannabis use disorder should continue with established behavioral and 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+GLP-1s+a+Viable+Option+to+Treat%2C+Prevent+SUDs%3F+-+Medscape+%40drcaplan&url=https%3A%2F%2Fwww.medscape.com%2Fviewarticle%2Fglp-1s-viable-option-treat-prevent-wide-range-substance-use-2026a10007x7)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.medscape.com%2Fviewarticle%2Fglp-1s-viable-option-treat-prevent-wide-range-substance-use-2026a10007x7)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+GLP-1s+a+Viable+Option+to+Treat%2C+Prevent+SUDs%3F+-+Medscape+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.medscape.com%2Fviewarticle%2Fglp-1s-viable-option-treat-prevent-wide-range-substance-use-2026a10007x7)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [AM News Update: March 16, 2026](https://cedclinic.com/cannabis-use-by-older-adults-mental-decline-2026/) - Could President Trump’s marijuana order bring medical cannabis to Tennessee? – YouTube - Daily Digest 2026-03-07 📰 Source: [https://www.medscape.com/viewarticle/glp-1s-viable-option-treat-prevent-wide-range-substance-use-2026a10007x7](https://www.medscape.com/viewarticle/glp-1s-viable-option-treat-prevent-wide-range-substance-use-2026a10007x7) Further Reading Evidence Watch[AM Study Update: March 16, 2026](https://cedclinic.com/cannabis-research-clinical-update-march-16-2026/) Cannabis Policy Wire[AM Policy Update: March 16, 2026](https://cedclinic.com/dea-scheduling-cannabis-rescheduling-march-16-2026/) Research Digest[AM News Update: March 16, 2026](https://cedclinic.com/cannabis-use-by-older-adults-mental-decline-2026/) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [GLP-1 medications get at the heart of addiction, study finds](https://cedclinic.com/glp-1-medications-addiction-treatment/) Discover how GLP-1 medications may influence addiction pathways and offer new treatment possibilities. [Read More](https://cedclinic.com/glp-1-medications-addiction-treatment/) [GLP-1s show promise in treating addiction – MSN](https://cedclinic.com) Explore the promising role of GLP-1s in addiction treatment as reported by MSN. [Learn More](https://cedclinic.com) Study Finds Weight Loss Drugs May Reduce Addiction Risk – RTTNews A study highlights the potential of weight loss drugs to reduce addiction risk, relevant to GLP-1 receptor agonists. Discover Insights ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).